Amgen Inc.
AMGN · Healthcare
$438.12
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
Schwab U.S. Dividend Equity vs. Vanguard Dividend Appreciation: Which ETF Looks Better for Your Portfolio?
Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year returns (29.5% vs 17.1%) and lower volatility, making it the analyst's preferred choice for income investors seeking higher yields.
AMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide is entering a competitive obesity market dominated by Novo Nordisk and Eli Lilly. The drug showed up to 20% average weight loss in phase II trials and offers a key advantage with once-monthly or less-frequent dosing compared to weekly injections from competitors. While MariTide trails competitors' efficacy and market presence, the massive obesity market projected to reach $114 billion by 2030 could support multiple players, allowing MariTide to carve out a meaningful position based on convenience and adherence.
Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
The Invesco Pharmaceuticals ETF (PJP) is a passively managed fund tracking the Dynamic Pharmaceutical Intellidex Index with $541.13 million in assets. It offers broad exposure to U.S. pharmaceutical companies with a 0.57% expense ratio and 0.82% dividend yield. The ETF has gained 24.96% year-to-date and 41.74% over the past year but carries higher risk with a beta of 0.45 and 16.02% standard deviation. It holds 32 stocks with top positions in Abbott Laboratories, Amgen, and Abbvie, and carries a Zacks ETF Rank of 3 (Hold).
If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio
As concerns grow about a potential AI market slowdown due to inflation, rate hikes, and geopolitical tensions, investors should consider diversifying into dividend-focused ETFs like SCHD. The Schwab U.S. Dividend Equity ETF offers exposure to 100 stable, dividend-paying stocks across multiple sectors, providing a defensive hedge against AI stock volatility while delivering steady income and historical returns of 243% over the past decade.